Difference between revisions of "Talimogene laherparepvec (Imlygic)"
(Created page with "==General information== Class/mechanism: Oncolytic Viral Therapy <br>Route: PO <br>Extravasation: n/a For conciseness and simplicity, HemOnc.org currently will focus on treat...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
Class/mechanism: Oncolytic Viral Therapy | Class/mechanism: Oncolytic Viral Therapy | ||
| − | <br>Route: | + | <br>Route: SC (injectable) |
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 05:40, 28 October 2015
General information
Class/mechanism: Oncolytic Viral Therapy
Route: SC (injectable)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, , UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Patient counseling information can be found on Amgen Patient Medication Guide[1]
Also Known As
- OncoVEXGM-CSF
- T-VEC
- Imlygic
Prescribing information
Prescribing information for healthcare providers
References
Andtbacka, H et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015:2812-2814. 3 Lawler SE, Chiocca EA. Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. J Clin Oncol. 2015;33(25):2812-4.